Newly Diagnosed Multiple Myeloma (NDMM), Phase 3, Melphalan+Autologous PBSCT+Placebo Maintenance, Immunomodulators (IMiD), Melphalan+Autologous PBSCT+Lenalidomide Maintenance
### Instruction:
Identify the study with the following condition. 
### Input:
Newly Diagnosed Multiple Myeloma (NDMM), Phase 3, Melphalan+Autologous PBSCT+Placebo Maintenance, Immunomodulators (IMiD), Melphalan+Autologous PBSCT+Lenalidomide Maintenance 
### Output:
Popular Name is CALGB, Study ID is NCT00114101